Zenotech Laboratories Ltd. (ZENOTECH) — Tipsheet https://tipsheet.markets/company/zenotech/ Every Tipsheet Editorial note covering Zenotech Laboratories Ltd. (ZENOTECH), newest first. Grounded in BSE/NSE primary-source filings. en-in Tue, 28 Jul 2026 14:38:36 GMT Zenotech swings to ₹45.55 lakh net loss in Q1 on higher costs https://tipsheet.markets/zenotech-zenotech-swings-to-45-55-lakh-net-loss-in-q1-on-higher-costs-128697/ https://tipsheet.markets/zenotech-zenotech-swings-to-45-55-lakh-net-loss-in-q1-on-higher-costs-128697/ Tue, 28 Jul 2026 14:49:05 GMT Revenue from operations rises 11% but employee and other expenses push the nano-cap pharma company into the red, versus a profit of ₹98.96 lakh a year ago. Revenue from operations rises 11% but employee and other expenses push the nano-cap pharma company into the red, versus a profit of ₹98.96 lakh a year ago.

What’s new

  • Net loss of ₹45.55 lakh for Q1 June 2026 against a ₹98.96 lakh profit a year ago.
  • Revenue from operations up 11% to ₹959.64 lakh.
  • Employee and other expenses pushed the company into the red.

Why it matters

For a ₹279-cr market-cap pharma with zero debt, the swing to loss is a meaningful deviation even if quarterly results are routine filings. Revenue growth couldn't offset cost pressures, raising questions about margin trajectory, particularly given the company's trailing PAT decline of 356.3%.

What we’re watching

  • Whether cost control measures emerge in the next quarter's disclosure.
  • Any change in revenue composition or one-off expense items.
  • Management commentary during the AGM on the earnings outlook.

The full read

Zenotech Laboratories reported a net loss of ₹45.55 lakh for the June quarter, swinging from a profit of ₹98.96 lakh a year earlier. Revenue rose 11% to ₹959.64 lakh, but employee and other expenses ate into margins. For a ₹279-cr market-cap pharma with zero debt and a trailing ROE of 5.8%, the loss stands out, especially as trailing revenue is down 18.6% and PAT has slumped 356.3%. The AGM scheduling for September is routine. One quarter doesn't make a trend, but for a company that was profitable a year ago, this is a step back. Whether cost pressures ease in coming quarters will determine if this is a blip or a shift.

Primary source: BSE · NSE

]]> Earnings Tipsheet Editorial Zenotech posts ₹45.55 lakh net loss in Q1 as costs surge https://tipsheet.markets/zenotech-zenotech-posts-45-55-lakh-net-loss-in-q1-as-costs-surge-128690/ https://tipsheet.markets/zenotech-zenotech-posts-45-55-lakh-net-loss-in-q1-as-costs-surge-128690/ Tue, 28 Jul 2026 14:44:15 GMT Zenotech Laboratories swung to a net loss of ₹45.55 lakh in Q1 FY27 from a profit of ₹98.96 lakh a year earlier, as expenses outpaced revenue growth of 11%. Zenotech Laboratories swung to a net loss of ₹45.55 lakh in Q1 FY27 from a profit of ₹98.96 lakh a year earlier, as expenses outpaced revenue growth of 11%.

What’s new

  • Zenotech reported a net loss of ₹45.55 lakh in Q1 FY27, reversing a profit of ₹98.96 lakh.
  • Revenue rose 11% to ₹959.64 lakh but total expenses rose to ₹1,164.86 lakh from ₹895.48 lakh.
  • Board scheduled 37th AGM for 25 September 2026 via videoconference.

Why it matters

For a company with a market cap of just ₹279 cr, a swing from profit to loss in a single quarter is significant. Employee and other costs are squeezing margins. The question is whether management can contain the cost surge without sacrificing growth.

What we’re watching

  • Whether the company can rein in expenses in coming quarters.
  • Any explanation from management on the cost increase.
  • Impact on the full-year outlook for a nano-cap pharma.

The full read

Zenotech Laboratories reported a net loss of ₹45.55 lakh in Q1 FY27, swinging from a ₹98.96 lakh profit a year earlier. Revenue crept up 11% to ₹959.64 lakh, but costs surged to ₹1,164.86 lakh — a 30% jump. The culprit: higher employee and other expenses. For a ₹279 cr market-cap pharma with zero debt, the loss isn't terminal, but it's a sharp reversal. Trailing PAT was already down 356%; this quarter accelerates the slide. The AGM notice is routine. The real question is whether management can contain costs without sacrificing the revenue growth that is still there.

Primary source: BSE · NSE

]]> Earnings Tipsheet Editorial